Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Mainz Biomed B.V. ( (MYNZ) ).
On September 26, 2025, Mainz Biomed N.V. released its Management’s Discussion and Analysis of Financial Condition and Results of Operations, along with its unaudited financial statements for the first half of 2025. The company reported a significant decrease in revenue by 45% compared to the same period in 2024, primarily due to strategic decisions to cease direct-to-consumer sales and sell its European Oncology Lab business. Despite a reduction in total revenue, Mainz Biomed managed to improve its gross margin from 61% to 66% through cost efficiencies and increased sales to lab partners. The company also highlighted its restructuring efforts in 2024, which included a reduction in operating costs and personnel, contributing to a decrease in overall expenses.
The most recent analyst rating on (MYNZ) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Mainz Biomed B.V. stock, see the MYNZ Stock Forecast page.
Spark’s Take on MYNZ Stock
According to Spark, TipRanks’ AI Analyst, MYNZ is a Neutral.
Mainz Biomed B.V. faces significant financial challenges with negative profitability and high leverage, which are the most impactful factors on the stock score. Technical indicators suggest a bearish trend, and the absence of valuation metrics like P/E ratio and dividend yield further weigh down the score. The lack of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on MYNZ stock, click here.
More about Mainz Biomed B.V.
Mainz Biomed B.V. operates in the biotechnology industry, focusing on the development and sale of in-vitro diagnostic tests for early cancer detection. Their flagship product, ColoAlert, is marketed in European markets, and they are working on next-generation colorectal cancer screening products for future launch in the U.S. and Europe. The company is also developing tests for pancreatic cancer and conducting research to expand its product portfolio.
Average Trading Volume: 135,235
Technical Sentiment Signal: Sell
Current Market Cap: $7.37M
Find detailed analytics on MYNZ stock on TipRanks’ Stock Analysis page.